Trade CNS Pharmaceuticals, Inc. - CNSP CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Trading Conditions
| Long position overnight fee | -0.0225% |
| Short position overnight fee | -0.0219% |
| Overnight fee time | 21:00 (UTC) |
| Min traded quantity | 1 |
| Currency | USD |
| Margin | 20% |
| Stock exchange | United States of America |
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 0.24 |
| Open* | 0.24 |
| Day's Range* | 0.24 - 0.24 |
| 1-Year Change* | 14.29% |
| Volume | N/A |
| Average Vol. (3m) | 12.9565 |
| 52 wk Range | N/A |
| Market Cap | 10.0562 |
| P/E Ratio | N/A |
| Shares Outstanding | 40032500 |
| Revenue | N/A |
| EPS | -0.4611 |
| Dividend (Yield %) | N/A |
| Beta | N/A |
| Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Aug 11, 2022 | 0.24 | 0.00 | 0.00% | 0.24 | 0.24 | 0.24 |
| Aug 10, 2022 | 0.24 | 0.01 | 4.35% | 0.23 | 0.24 | 0.23 |
| Aug 9, 2022 | 0.24 | 0.00 | 0.00% | 0.24 | 0.24 | 0.22 |
| Aug 8, 2022 | 0.23 | 0.01 | 4.55% | 0.22 | 0.24 | 0.22 |
| Aug 5, 2022 | 0.21 | -0.01 | -4.55% | 0.22 | 0.22 | 0.21 |
| Aug 4, 2022 | 0.21 | 0.00 | 0.00% | 0.21 | 0.21 | 0.21 |
| Aug 3, 2022 | 0.20 | 0.00 | 0.00% | 0.20 | 0.20 | 0.20 |
| Aug 2, 2022 | 0.20 | 0.00 | 0.00% | 0.20 | 0.20 | 0.20 |
| Aug 1, 2022 | 0.20 | -0.01 | -4.76% | 0.21 | 0.21 | 0.20 |
| Jul 29, 2022 | 0.20 | -0.01 | -4.76% | 0.21 | 0.21 | 0.20 |
| Jul 28, 2022 | 0.20 | 0.00 | 0.00% | 0.20 | 0.20 | 0.20 |
| Jul 27, 2022 | 0.20 | 0.00 | 0.00% | 0.20 | 0.21 | 0.20 |
| Jul 26, 2022 | 0.20 | -0.01 | -4.76% | 0.21 | 0.21 | 0.20 |
| Jul 25, 2022 | 0.21 | 0.00 | 0.00% | 0.21 | 0.22 | 0.21 |
| Jul 21, 2022 | 0.22 | 0.01 | 4.76% | 0.21 | 0.22 | 0.21 |
| Jul 20, 2022 | 0.22 | -0.01 | -4.35% | 0.23 | 0.23 | 0.22 |
| Jul 19, 2022 | 0.21 | -0.02 | -8.70% | 0.23 | 0.23 | 0.21 |
| Jul 18, 2022 | 0.23 | -0.02 | -8.00% | 0.25 | 0.25 | 0.22 |
| Jul 15, 2022 | 0.23 | -0.01 | -4.17% | 0.24 | 0.25 | 0.23 |
| Jul 14, 2022 | 0.24 | -0.01 | -4.00% | 0.25 | 0.26 | 0.24 |
CNS Pharmaceuticals, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 0.21511 | 7.16863 | 3.83298 | 9.45461 | 14.0273 |
| Selling/General/Admin. Expenses, Total | 0.18247 | 0.86052 | 1.97864 | 4.39287 | 4.68084 |
| Research & Development | 0.03264 | 0.02127 | 1.85433 | 5.06173 | 9.34645 |
| Unusual Expense (Income) | 0 | 6.28684 | 0 | ||
| Operating Income | -0.21511 | -7.16863 | -3.83298 | -9.45461 | -14.0273 |
| Interest Income (Expense), Net Non-Operating | -0.00426 | -0.0467 | -0.04423 | -0.00326 | -0.00929 |
| Other, Net | 0 | -0.17657 | 0 | ||
| Net Income Before Taxes | -0.21936 | -7.3919 | -3.87721 | -9.45787 | -14.0366 |
| Net Income After Taxes | -0.21936 | -7.3919 | -3.87721 | -9.45787 | -14.0366 |
| Net Income Before Extra. Items | -0.21936 | -7.3919 | -3.87721 | -9.45787 | -14.0366 |
| Total Extraordinary Items | 0 | ||||
| Net Income | -0.21936 | -7.3919 | -3.87721 | -9.45787 | -14.0366 |
| Income Available to Common Excl. Extra. Items | -0.21936 | -7.3919 | -3.87721 | -9.45787 | -14.0366 |
| Income Available to Common Incl. Extra. Items | -0.21936 | -7.3919 | -3.87721 | -9.45787 | -14.0366 |
| Diluted Net Income | -0.21936 | -7.3919 | -3.87721 | -9.45787 | -14.0366 |
| Diluted Weighted Average Shares | 15.712 | 15.712 | 13.6479 | 16.6184 | 26.3533 |
| Diluted EPS Excluding Extraordinary Items | -0.01396 | -0.47046 | -0.28409 | -0.56912 | -0.53263 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Diluted Normalized EPS | -0.01396 | -0.07033 | -0.28409 | -0.56912 | -0.53263 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 3.60966 | 3.81132 | 3.8134 | 2.79292 | 2.78177 |
| Selling/General/Admin. Expenses, Total | 1.40278 | 1.14634 | 1.23539 | 0.89633 | 1.26041 |
| Research & Development | 2.20687 | 2.66498 | 2.57802 | 1.89658 | 1.52136 |
| Operating Income | -3.60966 | -3.81132 | -3.8134 | -2.79292 | -2.78177 |
| Interest Income (Expense), Net Non-Operating | -0.00375 | -0.00235 | -0.00095 | -0.00224 | -0.00257 |
| Net Income Before Taxes | -3.6134 | -3.81367 | -3.81435 | -2.79515 | -2.78434 |
| Net Income After Taxes | -3.6134 | -3.81367 | -3.81435 | -2.79515 | -2.78434 |
| Net Income Before Extra. Items | -3.6134 | -3.81367 | -3.81435 | -2.79515 | -2.78434 |
| Net Income | -3.6134 | -3.81367 | -3.81435 | -2.79515 | -2.78434 |
| Income Available to Common Excl. Extra. Items | -3.6134 | -3.81367 | -3.81435 | -2.79515 | -2.78434 |
| Income Available to Common Incl. Extra. Items | -3.6134 | -3.81367 | -3.81435 | -2.79515 | -2.78434 |
| Diluted Net Income | -3.6134 | -3.81367 | -3.81435 | -2.79515 | -2.78434 |
| Diluted Weighted Average Shares | 24.6644 | 25.4327 | 27.4438 | 27.8385 | 38.8083 |
| Diluted EPS Excluding Extraordinary Items | -0.1465 | -0.14995 | -0.13899 | -0.10041 | -0.07175 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.1465 | -0.14995 | -0.13899 | -0.10041 | -0.07175 |
- Annual
- Quarterly
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 0.16219 | 0.58813 | 7.89391 | 15.4958 | 7.47745 |
| Cash and Short Term Investments | 0.11054 | 0.28274 | 7.24129 | 14.0395 | 5.00452 |
| Cash & Equivalents | 0.11054 | 0.28274 | 7.24129 | 14.0395 | 5.00452 |
| Prepaid Expenses | 0.05165 | 0.033 | 0.65262 | 1.45635 | 2.47293 |
| Other Current Assets, Total | 0 | 0.2724 | 0 | ||
| Total Assets | 0.16219 | 0.68333 | 7.91208 | 15.8534 | 8.75739 |
| Other Long Term Assets, Total | 0 | 0.0952 | 0 | 0.33414 | 1.26383 |
| Total Current Liabilities | 0.22073 | 1.23263 | 0.311 | 1.90543 | 2.13557 |
| Accounts Payable | 0.0425 | 0.12807 | 0.24367 | 0.94633 | 1.52282 |
| Payable/Accrued | 0.015 | 0.00079 | 0.04583 | 0 | |
| Accrued Expenses | 0.0414 | 0.0236 | 0.0215 | 0.5198 | 0.22495 |
| Notes Payable/Short Term Debt | 0.12183 | 0.31692 | 0 | 0.43929 | 0.38779 |
| Other Current Liabilities, Total | 0 | 0.76325 | 0 | ||
| Total Liabilities | 0.22073 | 1.23263 | 0.311 | 1.90543 | 2.13557 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | -0.05853 | -0.5493 | 7.60108 | 13.948 | 6.62182 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.01027 | 0.0127 | 0.01645 | 0.02386 | 0.02793 |
| Additional Paid-In Capital | 0.15056 | 7.04927 | 19.0731 | 34.8705 | 41.5768 |
| Retained Earnings (Accumulated Deficit) | -0.21936 | -7.61126 | -11.4885 | -20.9463 | -34.9829 |
| Total Liabilities & Shareholders’ Equity | 0.16219 | 0.68333 | 7.91208 | 15.8534 | 8.75739 |
| Total Common Shares Outstanding | 15.712 | 15.712 | 16.4502 | 23.8561 | 27.9272 |
| Property/Plant/Equipment, Total - Net | 0.01817 | 0.02343 | 0.01611 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 12.7864 | 13.8835 | 11.1558 | 7.47745 | 14.7332 |
| Cash and Short Term Investments | 11.0752 | 6.88557 | 8.32622 | 5.00452 | 12.4405 |
| Cash & Equivalents | 11.0752 | 6.88557 | 8.32622 | 5.00452 | 12.4405 |
| Total Receivables, Net | 0.13265 | 3.70177 | |||
| Accounts Receivable - Trade, Net | 0.13265 | 0.13265 | |||
| Prepaid Expenses | 1.57852 | 3.29615 | 2.82961 | 2.47293 | 2.29267 |
| Total Assets | 13.1446 | 14.2385 | 11.5075 | 8.75739 | 15.8719 |
| Property/Plant/Equipment, Total - Net | 0.02411 | 0.0209 | 0.01753 | 0.01611 | 0.01273 |
| Other Long Term Assets, Total | 0.33414 | 0.33414 | 0.33414 | 1.26383 | 1.12596 |
| Total Current Liabilities | 1.90176 | 1.83075 | 2.40743 | 2.13557 | 1.0693 |
| Accounts Payable | 1.05768 | 0.89249 | 1.46157 | 1.52282 | 0.48972 |
| Accrued Expenses | 0.53494 | 0.76068 | 0.90122 | 0.22495 | 0.30701 |
| Notes Payable/Short Term Debt | 0.30913 | 0.17758 | 0.04463 | 0.38779 | 0.27257 |
| Total Liabilities | 1.90176 | 1.83075 | 2.40743 | 2.13557 | 1.0693 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 11.2429 | 12.4078 | 9.10007 | 6.62182 | 14.8026 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.02535 | 0.02738 | 0.02746 | 0.02793 | 0.04003 |
| Additional Paid-In Capital | 35.7772 | 40.7538 | 41.2604 | 41.5768 | 52.5298 |
| Retained Earnings (Accumulated Deficit) | -24.5597 | -28.3734 | -32.1878 | -34.9829 | -37.7673 |
| Total Liabilities & Shareholders’ Equity | 13.1446 | 14.2385 | 11.5075 | 8.75739 | 15.8719 |
| Total Common Shares Outstanding | 25.3528 | 27.3795 | 27.4607 | 27.9272 | 40.0325 |
- Annual
- Quarterly
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -0.21936 | -7.3919 | -3.87721 | -9.45787 | -14.0366 |
| Cash From Operating Activities | -0.1122 | -0.71639 | -3.55347 | -7.31802 | -13.5383 |
| Non-Cash Items | 0.05992 | 6.59174 | 0.7474 | 1.29498 | 1.72384 |
| Cash Taxes Paid | 0 | 0 | 0 | 0 | 0 |
| Cash Interest Paid | 0 | 0 | 0.00399 | 0.00171 | 0.00977 |
| Changes in Working Capital | 0.04725 | 0.08378 | -0.42562 | 0.83378 | -1.23864 |
| Cash From Financing Activities | 0.22274 | 1.16098 | 10.2598 | 14.1342 | 4.50908 |
| Financing Cash Flow Items | 0 | 0.47048 | 0 | -0.045 | 0 |
| Issuance (Retirement) of Stock, Net | 0.10092 | 0.3905 | 10.2948 | 14.2222 | 4.98657 |
| Issuance (Retirement) of Debt, Net | 0.12183 | 0.3 | -0.035 | -0.04308 | -0.47749 |
| Net Change in Cash | 0.11054 | 0.44459 | 6.68616 | 6.79821 | -9.03498 |
| Cash From Operating Activities | 0.00196 | 0.0111 | 0.01307 | ||
| Cash From Investing Activities | -0.02012 | -0.01795 | -0.00575 | ||
| Capital Expenditures | -0.02012 | -0.01795 | -0.00575 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -3.6134 | -7.42708 | -11.2414 | -14.0366 | -2.78434 |
| Cash From Operating Activities | -3.30805 | -8.30599 | -10.3015 | -13.5383 | -3.0772 |
| Cash From Operating Activities | 0.003 | 0.00621 | 0.00958 | 0.01307 | 0.00338 |
| Non-Cash Items | 0.43068 | 0.90029 | 1.40694 | 1.72384 | 0.33669 |
| Cash Taxes Paid | 0 | 0 | 0 | 0 | 0 |
| Cash Interest Paid | 0.00421 | 0.00721 | 0.00721 | 0.00977 | 0.00288 |
| Changes in Working Capital | -0.12833 | -1.78541 | -0.4766 | -1.23864 | -0.63292 |
| Cash From Investing Activities | -0.00367 | -0.00367 | -0.00367 | -0.00575 | 0 |
| Capital Expenditures | -0.00367 | -0.00367 | -0.00367 | -0.00575 | 0 |
| Cash From Financing Activities | 0.34743 | 1.15574 | 4.59191 | 4.50908 | 10.5132 |
| Issuance (Retirement) of Stock, Net | 0.47759 | 1.41745 | 4.98657 | 4.98657 | 10.6284 |
| Issuance (Retirement) of Debt, Net | -0.13016 | -0.26171 | -0.39466 | -0.47749 | -0.11522 |
| Net Change in Cash | -2.96429 | -7.15392 | -5.71327 | -9.03498 | 7.43598 |
| Financing Cash Flow Items | 0 | 0 |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group 427000+
Traders
71000+
Active clients monthly
$46000000+
Monthly investing volume
$17000000+
Try now Withdrawn each month
CNS Pharmaceuticals, Inc. Company profile
About CNS Pharmaceuticals Inc
CNS Pharmaceuticals Inc. is a clinical pharmaceutical company. The Company is focused on development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The Company is developing its lead drug candidate, Berubicin for the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs, which intercalates into Deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. The Company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, CNS Pharmaceuticals Inc revenues was not reported. Net loss increased 48% to $14M. Higher net loss reflects Research and development increase of 85% to $9.3M (expense), Selling/General/Admin Expense increase of 7% to $4.7M (expense), Interest expense increase from $3K to $9K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.57 to -$0.53.
| Industry: | Biotechnology & Medical Research (NEC) |
2100 West Loop S Ste 900
HOUSTON
TEXAS 77027-3522
US
Income statement
News
Crypto market wrap: Sector treads water amid choppy trading
On average, digital coin prices remain flat as challenging week concludes
21:16, 12 August 2022
Mexico's Pemex requests $6.5 bln more funding for 'Dos Bocas' refinery -documents, source
Adds detail
19:26, 12 August 2022
3M demerger: MMM spin off Food Safety Business SpinCo merger with Neogen timing and details in full
3M (MMM) has revealed further details about its $5.3bn scheme to spin off its food-safety business. Added to the demerger of its health care products division, 3M is taking steps to lift its stock price.
19:21, 12 August 2022
US and Europe gas prices: What's the impact of heatwaves and hurricanes?
Demand for cooling is soaring in Europe as temperatures climb, adding to market pressure
18:51, 12 August 2022
Small cap index: A ‘small window’ for traders before Wyoming symposium
SWAV, SAIL, SWN, and AR lead Russell 2000 and small company stocks
17:42, 12 August 2022People Also Watch
US Crude Oil Spot
91.34 Price
| Long position overnight fee | 0.0139% |
| Short position overnight fee | -0.0310% |
| Overnight fee time | 21:00 (UTC) |
| Spread | 0.03 |
Trade now
Still looking for a broker you can trust?
Join the 427.000+ traders worldwide that chose to trade with Capital.com
